OCREVUS (Ocrelizumab)

OCREVUS (Ocrelizumab)

Regular price
$10,999.99 USD
Sale price
$10,999.99 USD
Regular price
Sold out
Unit price
Shipping calculated at checkout.

prescription refrigerated

What is this medication?

OCREVUS (Ocrelizumab)
CD20-directed cytolytic antibody

OCREVUS (Ocrelizumab) is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis.

How does this medication work? 

OCREVUS (Ocrelizumab) is presumed to bind to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, Ocrelizumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.

How should I take this medication? 

IV: Initial dose of 300mg intravenous infusion, followed 2 weeks later by 300mg intravenous infusion.  Subsequent dosing of 600mg intravenous infusion every 6 months.

Note: Hepatitis B virus screening is required before the first dose.  Premedicate with methylprednisolone (or an equivalent corticosteroid) and an antihistamine prior to each infusion.

What should I watch for while using this medication? 

Before starting OCREVUS (Ocrelizumab) make sure your physician is aware of any allergies or medications you currently take.  Discontinue Ocrelizumab if a life threatening or disabling infusion reaction occurs.  Vaccination with live-attenuated or live vaccines is not recommended during treatment with Ocrelizumab and after discontinuation, until B-cell repletion.  There is an increased risk of developing a malignancy, including breast cancer.

What if I miss a dose?

If a planned infusion is missed, administer as soon as possible; do not wait until the next scheduled dose. Reset the dose schedule to administer the next sequential dose 6 months after the missed dose is administered. Doses of OCREVUS (Ocrelizumab) must be separated by at least 5 months.

How should I store this medication?

Store vials at 2°C–8°C (36°F–46°F) in the outer carton to protect from light. Do not freeze or shake.  Prior to the start of the intravenous infusion, the content of the infusion bag should be at room temperature. Use the prepared infusion solution immediately. If not used immediately, store up to 24 hours in the refrigerator at 2°C–8°C (36°F–46°F) and 8 hours at room temperature up to 25°C (77°F), which includes infusion time. In the event an intravenous infusion cannot be completed the same day, discard the remaining solution.

What are the possible side effects of using this medication?

Upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory tract infections.

Note this is not a complete list of side effects for OCREVUS (Ocrelizumab), only common ones.